Curcumin Inhibits the Growth and Metastasis of Melanoma via miR-222-3p/SOX10/Notch Axis

Youqun Tang and Yanming Cao

Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan, China

Correspondence should be addressed to Yanming Cao; caoyanming8128@126.com

Received 10 March 2022; Revised 11 April 2022; Accepted 15 April 2022; Published 9 May 2022

Background. The aim of this study was to investigate the effect of curcumin on melanoma and its mechanism.

Methods. Curcumin (0, 0.125, 0.25, or 0.5 mg/ml) was utilized to treat A375 and HT144 cell lines. The MTT analysis was used to confirm the proliferation ability. Wound healing and transwell analysis showed the migration and invasion ability. Immuno fluorescence assay was used to demonstrate the effect of curcumin on SOX10 expression. Multiple bioinformatic analysis to confirm the SOX10 associated miRNA. The correlation of miR-222-3p and SOX10 was detected by Luciferase reporter assays. qRT-PCR showed the miR-222-3p level. Western blot analyzed the expression of SOX10, Notch1, and HES1 in melanoma cell treated with or without miR-222-3p inhibitor.

Results. Curcumin could inhibit the proliferation, migration, and invasion of melanoma cells. Furthermore, curcumin repress the expression of SOX10, Notch1, and HES-1, and increase the expression of miR-222-3p. And the miR-222-3p could directly target to SOX10 mRNA to inhibit its expression. In addition, inhibition of miR-222-3p expression reversed the inhibitory effect of curcumin the growth of melanoma cells.

Conclusion. Curcumin enhances the miR-222-3p level to reduce SOX10 expression, and ultimately inactivates the Notch pathway in repressing melanoma proliferation, migration, and invasion.

1. Introduction

Melanoma is one of the most lethal cancers among all skin cancers with a markedly low survival rate, resulting in a serious social burden. To make things worse, there is still no life-saving treatment for patients with advanced melanoma. The five-year survival rate in the early stages of the disease exceeds 95%, but in the later stages, survival rarely exceeds a year [1, 2]. Although there are currently six new drugs approved for the treatment of advanced melanoma (https://www.drugs.com/mtm/trametinib.html; https://www.accessdata.fda.gov/drugsatfda/docs/label/2014/125514lbl.pdf; https://www.ono.co.jp/eng/news/pdf/smcl140704.pdf), they fail to improve patient survival and are expensive. Therefore, it is necessary to find novel drugs for the treatment of this disease.

Curcumin, a polyphenol from curcuma longa (turmeric), was an important spice, food coloring, and traditional herbal medicine in human history. Due to its antiinflammatory and antioxidant properties, curcumin has been also reported to have significant health benefits, including improved brain function and anticancer/anti-therosclerotic properties [3]. A previous study has been indicated that curcumin could inhibit breast cancer cells proliferation and invasion via repressing the NF-κB inducing genes, including cyclinD and MMP-1 [4]. It has been suggested that curcumin could influence the G0/G1 phase arrest by MTA1- (metastasis-associated protein 1-) induced inactivation of Wnt/β-catenin pathway in the lung cancer cell [5]. In gastric cancer, curcumin could induce MMP proteins dissipation and cytochrome C into the cytosol in SGC-7901 cell lines, resulting
in the downregulation of migration ability and apoptosis escaping [6]. In colon cancer HCT116 and HT29 cells, curcumin could inhibit the level and activity of hexokinase II (HKII) by a concentration-dependent manner, inducing cell apoptosis [7]. There is also an increasing number of studies showing that curcumin can also induce apoptosis and inhibit proliferation of melanoma cancer cells [8]. Therefore, this study conducted an in-depth study on the mechanism of curcumin on melanoma cells.

Sex determining region Y-BOX 10 (SOX10) is a transcription factor, which involved in the occurrence and development of various cancers [9]. It has been indicated that SOX10 impedes the immunogenicity of melanoma cells through the IRF4-IRF1 axis [10]. In our previous study, we found that SOX10 mRNA and protein expression was obviously increased in melanoma tissue samples compared to normal tissue samples, which could significantly promote the melanoma cell proliferation via activating Notch pathway [11].

MicroRNAs (miRNAs) are noncoding RNAs that participate in a variety of cellular processes and can inhibit or promote tumorigenesis. At present, some miRNAs have been found to play a role in melanoma. For example, MiR-205 is cancer suppressor miRNA that is downregulated in melanoma [12], which is related to cell survival and invasion [13]. MiR-221/222 is also an oncogenic miRNA cluster that is often overexpressed in melanoma and enhances the proliferation of cancer cells [14].

Previous study was found that the tumor-suppressing effects of miR-222-3p have shown that miR-222-3p inhibited the level of PDCD10 to decrease the tumor metastasis via regulating Wnt/β-catenin signaling pathway in ovarian cancer [15]. Fu et al. found that the miRNA-222-3p/GNAI2/AKT axis inhibited epithelial ovarian cancer cell proliferation and migration [16]. However, it is unknown whether curcumin affects the expression of miR-222-3p and SOX10, and whether there is interaction between miR-222-3p and SOX10 in melanoma. Therefore, in this study, melanoma cells were used to investigate the mechanism of curcumin on melanoma in vitro, as well as the role of miR-222-3p and SOX10 in it, aiming to provide new therapeutic options for the clinical treatment of melanoma.

2. Methods

2.1. Bioinformatic Analysis. LinkedOmics (http://www.linkedomics.org/login.php), a publicly available database, includes 32 cancer types datasets based on TCGA database and 10 cancer types datasets based on CPTAC database [10]. This database was used to analysis the miRNAs correlated with SOX10 mRNA level. TargetScan (http://www.targetscan.org) was used to predict biological targets of miRNAs associated with SOX10 by searching for the presence of conserved sites that match the seed region of each miRNA [11]. The study was approved by the ethics committees of The Third Xiangya Hospital, Central South University.

2.2. Cell Culture and Treatment. A375 and HT144 cells were purchased from National Collection of Authenticated Cell Cultures. A375 and HT144 cell cultures were performed referring to our previous study [10]. The cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin in a 5% CO2 incubator at 37°C.

These cells were treated with different curcumin (S1848, Selleck) concentrations (0, 0.125, 0.25, or 0.5 mg/ml) for 48 hours at 37 degree centigrade. miRNA-222-3p mimics or inhibitors and SOX10 overexpression vectors were purchased from Ribobio (Guangzhou, China). The cells were seeded in 6-well plates and then transfected with 50 nM of miRNA mimic/NC, inhibitor/NC, and 500 ng recombinant plasmid, respectively, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 6 hours of transfection, the culture medium was replaced with fresh medium containing 10% FBS. All transfections were performed for 48 h, prior to harvesting for the following assays.

2.3. MTT Analysis. MTT analyses were performed as previously described [10]. Cells were seeded into 96-well plates at a density of 6 × 10^4/well. After adhering to the wall, curcumin was treated for 24, 48, and 72 h, respectively. Add 20μL 5 mg/mL MTT solution (Gefan Biotechnology Co., Ltd., Shanghai, China), and incubate in incubator for 4 hours. Discard the medium, and add 150μL DMSO to dissolve the crystal. The absorbance at OD450 was measured using an enzyme marker (SpectraMax M5, Molecular Devices, CA, USA).

2.4. Wound Healing Analysis. The cells were inoculated in 6-well plate at the density of 5 × 10^5/well and adhered to the wall for 24 hours. The cells were scratched with a pipette tip. At 0 h and 48 h, the wound was observed and photographed using a light microscope (Olympus), and the wound healing rate was calculated.

2.5. Transwell Assays. The A375 or HT144 cells were digested and resuspended in DMEM medium, then 2.5 × 10^5 cells were counted and inoculated in the upper chamber precoated with matrigel in the 24-well plates, and 750 μl of DMEM containing 10% FBS was added to the lower chamber and cultured at 37°C. After 24 h, 4% paraformaldehyde was used to fix the migrated cells for 30 min and dyed with 5% crystal violet for 15 min. A cotton swab was then used to remove the un-migrated cells in the upper chamber. Observe the cells under a microscope and take pictures.

2.6. Luciferase Reporter Assays. SOX10-3’UTR with or without mutation was subcloned into pGL3 promoter plasmid. 30,000 cells were seed into 24-well culture plates in phenol red-free medium. After transfection with miRNA-NC or miR-222-3p mimics for 48 h, the luciferase activity was determined by the Dual Luciferase Assay Kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

2.7. Quantitative Real-Time PCR. Quantitative real-time PCR assays were performed as previously described [10].
Using TRIZOL regent (Thermo Fisher Scientific) to extract total RNA of cells, the extracted mRNA was reverse transcribed into cDNA using the cDNA Reverse Transcription Kit (Thermo Fisher Scientific). SYBR Green PCR kit (TaKaRa, China) was used for qRT-PCR. The relative mRNA expression was calculated according to the 2−ΔΔCt method. Take GAPDH as the internal reference. Primer sequences used in this qRT-PCR are as follows: miR-222-3p: forward: 5-ACACCTCAGCTGGAGCTACATCGGCTACTGT-3, reverse: 5-CTCAACTGTTGTCTGTTGGA-3; U6: forward: 5-CTCGTTCGCCGACGCACA-3, reverse: 5-AACGCAAGGATTTGGCGTT-3; SOX10: forward: 5-CCTCAACAGATCGCTACACC-3, reverse: 5-CATATA GGAGAGGCCAGATAGA-3; and GAPDH: forward: 5-GTCT CCTCTGACCTCAACAGCG-3, reverse: 5-ACCA CCCCCTTGCTGCTAGCCAA-3.

2.8. Western Blot. The total protein was isolated from cells and tissues using RIPA lysis buffer (Santa Cruz, Dallas, USA). Protein samples were run on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Thermo Fisher Scientific). After blocking the PVDF membrane in TBS with 5% skim milk, add primary antibody to cells incubated with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. The membranes were incubated with 4% paraformaldehyde preheated at 37 °C. PVDF membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. After adding luminescent solution, the protein bands were visualized using the ECL system (Thermo Fisher Scientific), and the grayscale statistics was carried out by Image J software (Bio-Rad, USA). GAPDH is used as an internal reference.

2.9. Immunofluorescence. These A375 and HT144 cells were fixed with 4% paraformaldehyde preheated at 37 degree centigrade for 30 min at room temperature (RT). The cells were permeabilized by treating with 0.5% Triton X-100. Subsequently, cells were blocked with 5% normal goat serum (ZSGB-BIO) for 60 min at 37 degree centigrade and then incubated with SOX10 antibodies diluted 1:50 in PBS for overnight at 4 degree centigrade. Next day, the cells were washed with PBS and incubated with the secondary fluorescent antibody (diluted 1:500 with PBS) for 60 min and then stained with DAPI for 5 min. Finally, the cells were imaged using an inverted fluorescence microscope.

2.10. Statistical Analysis. All data analyses were performed using SPSS 24.0 software (SPSS, Inc., Chicago, IL, USA). The data were expressed as mean ± standard deviation (SD). One-way ANOVA was used to analyze the differences between multiple groups, and T test was used to analyze the differences between two groups. P < 0.05 was considered a significant difference.

3. Results

3.1. Curcumin Significantly Inhibit the Malignant Progression of Melanoma Cells. To confirm whether the pharmacologic effect of curcumin on the melanoma cells malignant progression, we utilized the 0.125 mg/ml, 0.25 mg/ml, and 0.5 mg/ml curcumin to test the cytotoxicity of curcumin in A375 and HT144 cell lines. We found that curcumin significantly decreased A375 and HT144 cell viability in a dose-dependent manner. Moreover, the 0.5 mg/ml curcumin has the strongest inhibitory effect on A375 and HT144 cell lines (Figure 1(a)). Subsequently, we found that the inhibition of curcumin on melanoma cell migration was also by a dose-dependent manner (Figure 1(b)), which 0.5 mg/ml curcumin had the best pharmacologic effects. The effect of 0.5 mg/ml curcumin on the invasion of melanoma cells was further determined by transwell. The results showed that 0.5 mg/ml curcumin could obviously reduce the invasion cell numbers compared to NC group (Figure 1(c)). These results indicated that curcumin had an important anticancer effect on melanoma cell.

3.2. SOX10 Can Interact with miRNA-222-3p in Melanoma Cells. In our previous study, we found that sex-determining region Y-related high mobility group-box 10 (SOX10) was an oncogenic role in melanoma progression, especially in proliferation [10]. Therefore, we detected the SOX10 expression in curcumin groups and NC group by immunofluorescence analysis, which showed that the expression of SOX10 was significantly decreased in curcumin groups compared to NC group by a dose-dependent manner (Figure 2(a)). In order to further explore the molecular mechanism of curcumin regulating SOX10, we made a correlation analysis among SOX10 and miRNAs based on TCGA database Melanoma datasets. We found 141 miRNAs were significantly and negatively correlated with SOX10 mRNA level (Figure 2(b)). Furthermore, we extracted miRNAs datasets that targeted SOX10 based on TargetScan database (http://www.targetscan.org). Then, the miRNAs between TCGA and TargetScan were generated by using Venn diagram (Figure 2(c)), which showed that 2 miRNAs, miRNA-222-3p and miRNA-221-3p, were negatively and directly correlated with SOX10 in melanoma patients. Furthermore, qRT-PCR was used to verify the expression of miRNA-222-3p and miRNA-221-3p in melanoma cells and its interaction with SOX10. The results indicated that miRNA-222-3p was significantly increased after curcumin treatment, while miRNA-221-3p was not significantly influenced by curcumin (Figure 2(d)). To demonstrate the direct effect of miRNA-222-3p on SOX10, a luciferase assay was performed. The results showed that the overexpression of miRNA-222-3p could significantly inhibit the expression of SOX10, while SOX10 mutation binding sites was not affected by miRNA-222-3p mimics (Figure 2(e)). Moreover, the mRNA level of SOX10 was significantly decreased by miRNA-222-3p mimics (Figure 2(f)).

3.3. Inhibition of miRNA-222-3p Can Reverse the anti-Tumor Effect of Curcumin. Moreover, we further detected the role of miRNA-222-3p in the progression of melanoma. We treated A375 and HT144 cell lines with curcumin or curcumin plus miRNA-222-3p inhibitor (Figure 3(a)). The cell proliferation was significantly decreased by curcumin,
which could be reversed by miRNA-222-3p inhibitor. The invasion ability of A375 and HT144 cell was also decreased by miRNA-222-3p but reversed by miRNA-222-3p inhibitor (Figure 3(b)). We further found curcumin could inhibit the expression of SOX10, Notch1, and Hes1, which could be reversed by miRNA-222-3p inhibitor (Figure 3(c)). Taken together, the curcumin enhances the miR-222-3p level to inhibit SOX10 expression, which inactivates the Notch pathway to impede the melanoma cell proliferation, migration, and invasion (Figure 3(d)).
4. Discussion

This study indicated the effect of curcumin on melanoma cell lines, including A375 and HT144 cells. We found that exposure to curcumin obviously repressed proliferation, migration, and invasion in melanoma cells. The proliferation, migration, and invasion ability were significantly decreased after treated with curcumin in a dose-dependent manner in melanoma cells. In the previous study, curcumin could enhance miR-98 level to inhibit LIN28A mRNA level, resulting in suppressing lung cancer cell growth and invasion [17]. Curcumin could also inhibit miR-7641 to enhance p16 expression, which led to the downregulated invasion and apoptosis escaping of bladder cancer cells [18]. Dou et al. found that curcumin inactivated Wnt/beta-catenin pathway to repress cell proliferation in colon cancer via enhancing miR-130a [19]. Our study indicated that curcumin serves a key role in the suppression of melanoma cell proliferation, migration, and invasion via enhancing miR-222-3p which targeted to SOX10. Furthermore, miR-222-3p inhibitor markedly reversed the effect of curcumin on melanoma cellular proliferation, migration, and invasion. Taken together, these results indicated that the miRNAs regulation was the significant way in anticancer molecular mechanisms for curcumin.

Melanoma is the most fatal form of malignant skin cancer with high invasiveness and arises from melanocytes [20]. At the molecular and cellular levels, curcumin inactivates EMT cascade and affects many targets involved in melanoma initiation and progression (e.g., BCI-2, MAPKS, P21, and some microRNAs) [21], which emerge with great potential for clinical applications. In this study, we found that the miR-222-3p/SOX10/Notch pathway was considered one of the most important mechanisms of the anticancer effect of curcumin. miR-222-3p played an anticancer role in ovarian cancer [22], but served as a oncogene in thyroid carcinoma [23], lung cancer [24], and osteosarcoma [25]. The paradoxical role may lie in the differential transcription levels of key downstream genes targeted by miR-222-3p in different cancer types, especially in melanoma. SOX10, an essential transcription factor, belongs to the SOX family of transcription factors, which involved in the occurrence, development, and progression of multiple cancer types [26]. We identified that curcumin had a repress effect on SOX10 expression to impede the proliferation, migration, and invasion ability via a dose-dependent manner in melanoma cells. These
results are consistent with previous studies, indicating that curcumin have an antitumous effect.

The Notch signaling pathway, an oncogene in melanomagenesis, was involved in cell fate decisions, tissue patterning, and morphogenesis during development, which was an evolutionarily conserved, intercellular signaling cascade [27]. Notch1 deficiency sensitizes melanoma cells to stress-induced cell death and repress proliferation ability in part by inhibiting CCND1, resulting in decreasing in melanoma growth [28]. Moreover, Notch pathway could interact with ERBB pathway [29], Nodal pathway [30], or canonical Wnt signaling pathway [31] to promote melanoma...
progression. Furthermore, He et al. found that curcumin could target Notch pathway to decelerate the development and progression of cervical cancer [32]. Yang and his colleagues suggested that curcumin could impede prostate cancer cell survival and metastasis via inactivating Notch-1 signaling pathway [33]. Curcumin could also mediate the death of esophageal cancer cells by modulating Notch signaling [34]. In hepatic cancer, curcumin promotes cell apoptosis and proliferation arrest through Notch pathway [35]. Similar results were observed in the study about the effect of curcumin on osteosarcoma cells [36]. The present study found curcumin inactivates Notch signaling pathway by regulating miR-222-3p/SOX10 axis in melanoma cell. Thus, our study shows that the inhibition of Notch signaling by curcumin may be highly conserved in multiple tumor types and further explains how curcumin regulates Notch signaling at the molecular level.

5. Conclusion

In summary, these results indicated that curcumin was a key role in impeding the proliferation, migration, and invasion ability of melanoma cells. Curcumin enhances the miR-222-3p level to reduce SOX10 expression and ultimately inactivates the Notch pathway in melanoma. According to the above, curcumin represents a potential therapeutic agent for the treatment of melanoma.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors report no conflict of interest in this work.

Authors’ Contributions

Yannming Cao and Youqun Tang participated in the design of this study, and they both performed the statistical analysis. Yannming Cao carried out the study and collected important background information. Yannming Cao and Youqun Tang drafted the manuscript. All authors read and approved the final manuscript.

References

[1] L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani, “Toward a molecular classification of melanoma,” *Journal of Clinical Oncology*, vol. 25, no. 12, pp. 1606–1620, 2007.

[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” *CA: a cancer journal for clinicians*, vol. 71, no. 1, pp. 7–33, 2021.

[3] A. B. Kunnumakkara, D. Bordoloi, G. Padmavathi et al., “Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases,” *British Journal of Pharmacology*, vol. 174, no. 11, pp. 1325–1348, 2017.

[4] Q. Liu, W. T. Y. Loo, S. C. W. Sze, and Y. Tong, "Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclin D and MMP-1 transcription," *Phytomedicine*, vol. 16, no. 10, pp. 916–922, 2009.

[5] Y. Lu, C. Wei, and Z. Xi, "Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway," *In Vitro Cellular & Developmental Biology. Animal*, vol. 50, no. 9, pp. 840–850, 2014.

[6] X. Xue, J.-L. Yu, D.-Q. Sun et al., "Curcumin induces apoptosis in SGC-7901 gastric adenocarcinoma cells via regulation of mitochondrial signaling pathways," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 9, pp. 3987–3992, 2014.

[7] K. Wang, H. Fan, Q. Chen et al., "Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro," *Anti-Cancer Drugs*, vol. 26, no. 1, pp. 15–24, 2015.

[8] W. Liao, W. Xiang, F. F. Wang, R. Wang, and Y. Ding, "Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress," *Biomedicine & Pharmacotherapy*, vol. 95, pp. 1177–1186, 2017.

[9] H. Yin, C. Qin, Y. Zhao et al., "SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors," *Clinical & Translational Oncology*, vol. 19, no. 8, pp. 1035–1044, 2017.

[10] S. Yokoyama, A. Takahashi, R. Kituchi et al., "SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 Axis," *Cancer Research*, vol. 81, no. 24, pp. 6131–6141, 2021.

[11] Y. Tang and Y. Cao, "SOX10 knockdown inhibits melanoma cell proliferation via notch signaling pathway," *Cancer management and research*, vol. Volume 13, pp. 7225–7234, 2021.

[12] N. Latchana, A. Ganju, J. H. Howard, and W. E. Carson III, "Micro RNA dysregulation in melanoma," *Surgical Oncology*, vol. 25, no. 3, pp. 184–189, 2016.

[13] S. Liu, M. T. Tetzlaff, A. Liu, B. Liegl-Atzwanger, J. Guo, and X. Xu, "Loss of microRNA205 expression is associated with melanoma progression," *Laboratory Investigation*, vol. 92, no. 7, pp. 1084–1096, 2012.

[14] V. Sun, W. B. Zhou, S. Majid, M. Kashani-Sabet, and A. A. Dar, "MicroRNA-mediated regulation of melanoma," *The British Journal of Dermatology*, vol. 171, no. 2, pp. 234–241, 2014.

[15] L. Fan, H. Lei, S. Zhang et al., "Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing mi R-222-3p transcription and upregulating PDCD10," *Theranostics*, vol. 10, no. 13, pp. 5895–5913, 2020.

[16] X. Fu, Y. Li, A. Alvero et al., "MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival," *Oncotarget*, vol. 7, no. 4, pp. 80633–80654, 2016.

[17] S. V. Vasaikar, P. Straub, J. Wang, and B. Zhang, "LinkedOmics: analyzing multi-omics data within and across 32 cancer types," *Nucleic Acids Research*, vol. 46, no. D1, pp. D956–D963, 2018.

[18] W. L. Liu, J. M. Chang, I. W. Chong et al., "Curcumin inhibits LIN-28A through the activation of miRNA-98 in the lung cancer cell line A549," *Molecules*, vol. 22, no. 6, p. 929, 2017.

[19] K. Wang, S.-L. Tan, Q. Lu et al., "Curcumin suppresses microRNA-7641-mediated regulation of p16 expression in..."
bladder cancer,” The American Journal of Chinese Medicine, vol. 46, no. 6, pp. 1357–1368, 2018.

[20] H. Dou, R. Shen, J. Tao et al., “Curcumin suppresses the colon cancer proliferation by inhibiting Wnt/β-catenin pathways via miR-130a,” Frontiers in pharmacology, vol. 8, p. 877, 2017.

[21] M. Bobos, “Histopathologic classification and prognostic factors of melanoma: a 2021 update,” Italian Journal of Dermatology and Venereology, vol. 156, no. 3, pp. 300–321, 2021.

[22] H. Mirzaei, G. Naseri, R. Rezaee et al., “Curcumin: a new candidate for melanoma therapy?,” International Journal of Cancer, vol. 139, no. 8, pp. 1683–1695, 2016.

[23] C. Zhang, Q. Chang, Y. Hu et al., “MiR-222-3p promotes the proliferation, migration and invasion of papillary thyroid carcinoma cells through targeting SLCA4A4,” Histology and histopathology, vol. 36, no. 11, pp. 1199–1207, 2021.

[24] W. Chen and X. Li, “MiR-222-3p promotes cell proliferation and inhibits apoptosis by targeting PUMA (BBC3) in non-small cell lung cancer,” Technology in cancer research & treatment, vol. 19, p. 153303820922558, 2020.

[25] J. Guo, Q. Liu, Z. Li, H. Guo, C. Bai, and F. Wang, “miR-222-3p promotes osteosarcoma cell migration and invasion through targeting TIMP3,” OncoTargets and therapy, vol. 11, pp. 8643–8653, 2018.

[26] L. Yu, F. Peng, X. Dong et al., “Sex-determining region Y chromosome-related high-mobility-group box 10 in cancer: a potential therapeutic target,” Frontiers in cell and developmental biology, vol. 8, p. 564740, 2020.

[27] Z.-C. Liu, Z.-X. Yang, J.-S. Zhou et al., “Curcumin regulates hepatoma cell proliferation and apoptosis through the Notch signaling pathway,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 3, pp. 714–718, 2014.

[28] Y. Li, J. Zhang, D. Ma et al., “Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling,” The FEBS Journal, vol. 279, no. 12, pp. 2247–2259, 2012.